Tarsus Pharmaceuticals (NASDAQ:TARS) Price Target Raised to $65.00

Tarsus Pharmaceuticals (NASDAQ:TARS) had its price target boosted by Oppenheimer from $63.00 to $65.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Separately, William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $54.20.

Tarsus Pharmaceuticals Price Performance

TARS opened at $44.83 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 6.99. Tarsus Pharmaceuticals has a 12 month low of $15.60 and a 12 month high of $52.99. The business has a 50 day simple moving average of $37.84 and a 200-day simple moving average of $32.53.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC purchased a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $61,000. Canada Pension Plan Investment Board acquired a new position in Tarsus Pharmaceuticals during the second quarter worth about $114,000. FMR LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 236.6% in the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Tarsus Pharmaceuticals by 33.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after purchasing an additional 1,530 shares during the last quarter. Finally, Bleakley Financial Group LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 1st quarter worth approximately $223,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.